Abbott 3Q11

3Q Revenues: $9.8 billion (+13%)

3Q Earnings: $303 million (-66%)

YTD Revenues: $28.5 billion (+13%)

YTD Earnings: $3.1 billion (+2%)

Comments: Pharmaceuticals sales were up 14% in the quarter to $4.3 billion.
Humira sales were up 26% to $2.1 billion. Kaletra sales were down 9% to $297.0 million. TRILIPIX/TriCor sales were up 2% to $419.0 million. Emerging markets sales were $2.6 billion, up 21%. Earnings in the quarter include a $1.5 billion pre-tax reserve for litigation related to Depakote. R&D expenses were $1.0 billion in the quarter, down 6%.